[Ended]Indonesian Neurology NMO Case Teleconference

Ver 1.55

Local Time At Main Venue

2017/02/07 (Tue) 14:00-120min, Jakarta Pusat,ID (UTC+07:00)

Organizer

Riwanti Estiasari

Contents

Neurology

Topics

Neuromyelitis Optic

A-26-year-old woman came to hospital due to excessive sleep since 1 month before admission. There were also intermittent fever and urinary incontinence. Her serum sodium level was low. The symptoms getting worse and her speech sometimes incoherent with hallucination and short term memory impairment. Serum AQP4 Ab was positive. She was diagnosed as NMOSD with AQP4 positive since 3 year ago with transverse myelitis as her first symptoms. She got methylprednisolone and plasmapheresis for her first attack continue with mycophenolate mofethyl for long term treatment. In the middle of treatment she experienced incoherent speech and personality changes. Lumbar puncture was performed and CSF showed PCR CMV positive. Mycophenolate mofethyl was withdrawal and she was given ganciclovir for her CMV. After 2 month she recover and can back to work normally. For current attack, we found no PCR CMV on her CSF and the IgM CMV also non reactive. We gave her methylprednisolone 500mg with plasmapheresis.

Connection Method

Vidyo

Style

Conference

Server At

Kyushu University

Chairs

Chair

Riwanti Estiasari
University of Indonesia / ID

Co-Chair1

Junichi Kira
Kyushu University Hospital / JP

Co-Chair2

Pukovisa Prawiroharjo
University of Indonesia / ID

Chief Engineer1

Nopa Krismanto
University of Indonesia / ID

Chief Engineer2

Tunggul Laksono
Brawijaya University / ID

Participating Institutions

Note: The institution shown in red is not confirmed.

City, Country

Institution

Moderator

Schedule

Precautions

• The conference will be recorded by the photos and movies.

• Pictures taken at the conference may be published in TEMDEC home page, annual report and conference presentations.

• Do not present the personal information of patients any in oral and presentation materials without obtaining the patient’s consent.

* For more information, please refer to the TEMDEC policy.